At the beginning of 1996 Pfizer was sitting on a new, potentially billion-dollar blockbuster drug, according to Wall Street analysts. The antibiotic Trovan was not yet approved by the FDA. Pfizer had enrolled thousands of adults in Trovan clinical trials and they wanted to debut the drug as a therapy for bacterial meningitis, but there were a number of problems. There was already an effective treatment for meningitis available, the antibiotic ceftriaxone. But Pfizer’s biggest problem was children.
In order to gain maximum market share and achieve the predicted $1 billion per year from this drug, Pfizer needed to develop an oral form that proved safe for pediatric use. But Trovan had never been tested on children, and in animal models it caused liver toxicity and joint damage. In addition, bacterial meningitis was rare in the U.S. There were thus not enough children suffering from it for a convincing clinical trial. However, as luck would have it, a ready pool of children suffering from the disease had suddenly, coincidentally, and inexplicably become available—in Africa!
https://new.finalcall.com/2020/12/1...LuAHK0Hh3zJ1mnLuCd5p6My4jPrR-bfJBsX_55QCBCIKo
In order to gain maximum market share and achieve the predicted $1 billion per year from this drug, Pfizer needed to develop an oral form that proved safe for pediatric use. But Trovan had never been tested on children, and in animal models it caused liver toxicity and joint damage. In addition, bacterial meningitis was rare in the U.S. There were thus not enough children suffering from it for a convincing clinical trial. However, as luck would have it, a ready pool of children suffering from the disease had suddenly, coincidentally, and inexplicably become available—in Africa!
https://new.finalcall.com/2020/12/1...LuAHK0Hh3zJ1mnLuCd5p6My4jPrR-bfJBsX_55QCBCIKo
